Defiance Autism Impact ETF

Fund Overview

The Defiance Autism Impact ETF (NASDAQ: ASD) is the first exchange-traded fund built around a single conviction: that the companies advancing autism therapeutics, diagnostics, education, and care deserve dedicated long-term capital.

Autism is not a single condition. It is a spectrum of neurological, developmental, behavioral, and biological differences that affects every individual — and every family — uniquely. There are currently no FDA-approved medications addressing the core symptoms of autism, and the broader ecosystem of support spans pharmaceuticals, genetic testing, behavioral health, specialized education, and assistive technology.

Built by parents living with autism every day, ASD channels capital toward the innovators working to expand what’s possible. Defiance has committed to donate 100% of the Fund’s net advisory profits during its first two years, and no less than 50% thereafter, to organizations supporting autism care, research, and services.

About the VettaFi Autism Impact Index

ASD seeks to track the VettaFi Autism Impact Index, designed to measure the performance of publicly traded global companies in developed markets that provide products, services, and/or research supporting the autism ecosystem — comprised of individuals on the autism spectrum and the broader neurodivergent community.

VettaFi screens the global universe of listed companies using revenue segmentation disclosures, clinical trials activity, product indication filings, and public company filings and investor materials. To be eligible at reconstitution, a company must have a market capitalization of at least $250 million and a three-month average daily trading value of at least $1 million, and its products, services, and/or research must have a material impact on or play a direct role in one or more of three core segments:

• Drugs & Behavior Therapeutics — Pharmaceuticals, biologics, and clinical services (including ABA, speech, and occupational therapy) addressing autism and related neurodevelopmental and behavioral conditions.
• Diagnostics & Assessment Tools — Clinical, digital, neurological, and AI-driven tools used in the identification, monitoring, or assessment of autism.
• Specialized Education & Educational Technology — Education platforms, digital learning systems, curriculum solutions, and school services designed for neurodivergent learners.

The Index is equally weighted at each reconstitution, reconstituted semi-annually after the market close on the third Friday of June and December, and rebalanced quarterly on the third Friday of March, June, September, and December.